angiotensin ii has been researched along with Venous Thromboembolism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chávez-Alderete, J; Loza-Mejía, MA; Maldonado, V | 1 |
| Gan, R; Georgius, P; Henshaw, DJE; Noble, EP; Rosoman, NP; Sommerfeld, N | 1 |
2 other study(ies) available for angiotensin ii and Venous Thromboembolism
| Article | Year |
|---|---|
Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19.
Topics: Alveolar Epithelial Cells; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Complement Activation; COVID-19; COVID-19 Drug Treatment; Cytokines; Disease Models, Animal; Drug Repositioning; Endothelial Cells; Gene Expression Regulation; Humans; Immunologic Factors; Inflammation; Lymphocyte Subsets; Microcirculation; Oxidative Stress; Pandemics; Pentoxifylline; Rats; Receptors, Virus; Renin-Angiotensin System; SARS-CoV-2; Signal Transduction; Venous Thromboembolism | 2020 |
COVID-19 as a viral functional ACE2 deficiency disorder with ACE2 related multi-organ disease.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Anticoagulants; Cardiovascular Diseases; COVID-19; Humans; Hypertension; Models, Theoretical; Peptide Fragments; Renin-Angiotensin System; Respiration; Risk Factors; Venous Thromboembolism; Virus Internalization | 2020 |